Kitazawa. Takio T; Kaiya. Hiroyuki H; Taneike. Tetsuro T
The study looked at how different ghrelin‑related peptides affect the movement of a chicken's gut in a lab dish. Only the chicken version of ghrelin made the gut muscles contract, and this effect depended on the gut region and a specific chemical tag on the peptide. The synthetic peptide GHRP‑6, which some people use to boost growth hormone, did not cause any gut contraction in chickens.
Kaiya. Hiroyuki H; Miura. Tohru T; Matsuda. Kouhei K; Miyazato. Mikiya M; Kangawa. Kenji K
Scientists found four different ghrelin receptors in goldfish, split into two main types. One of these receptors can be blocked by a modified version of the peptide GHRP-6, but this was only shown in fish, not humans. Fasting changed the levels of some of these receptors, hinting they help control energy use.
Tanriverdi. F F; Unluhizarci. K K; Selcuklu. A A; Casanueva. F F FF; Kelestimur. F F
A 20‑year‑old amateur kickboxer got a head injury during a bout and later felt less interested in sex and had trouble getting an erection. Blood tests showed low testosterone and a bit high prolactin, but his growth‑hormone response to a GHRH + GHRP‑6 stimulation test was normal. Within a few months his hormone levels and symptoms went back to normal, showing the problem was temporary.
Yada. T T; Kaiya. H H; Mutoh. K K; Azuma. T T; Hyodo. S S; Kangawa. K K
In rainbow trout, the hormone ghrelin makes immune cells more active, boosting their ability to produce reactive oxygen species that help kill pathogens. This effect depends on the ghrelin receptor (GHS‑R) and involves the cells making their own growth hormone. Blocking the receptor with a compound called GHRP‑6 stops the boost.
In lab-grown human aortic cells, the hormone ghrelin can stop a harmful signal (angiotensin II) that makes these cells move around, which is part of how blood vessels remodel. This blocking effect needs a cell signaling pathway involving cAMP and PKA, and it disappears when a ghrelin‑blocking peptide (a version of GHRP‑6) is added.
Sirotkin. Alexander V AV; Meszarošová. Monika M; Grossmann. Roland R; Benčo. Andrej...
A study on pig ovarian cells found that both a ghrelin receptor blocker (D‑Lys3‑GHRP‑6) and a ghrelin activator (ghrelin‑1‑18) boost cell growth, stop cell death, and increase hormone production. Because the same effects happen with a blocker, the results likely aren’t due to the usual ghrelin receptor, and the findings are limited to lab dishes, not humans.
The study shows that giving cells a gene that makes a hormone called POMC can shrink melanoma tumors in mice. This effect works because a piece of POMC, alpha‑MSH, blocks a cancer‑promoting pathway (NF‑kB/COX‑2). When the researchers used GHRP‑6, which blocks alpha‑MSH, the anti‑cancer benefit disappeared, suggesting GHRP‑6 can interfere with this protective mechanism.
Lania. A A; Mantovani. G G; Ferrante. E E; Zavanone. L M LM; Locatelli. M M; Corbetta. S S; Beck-Pec...
In pituitary tumors that make too much growth hormone, the hormone GnRH can raise both calcium inside the cells and a messenger called cAMP, which helps release growth hormone. The peptide GHRP‑6, which some people use to try to boost growth hormone, only raised calcium and did not change cAMP levels in these tumor cells. This suggests that GHRP‑6 may not trigger the same growth‑hormone‑releasing pathways that GnRH does, at least in this abnormal tissue.
Lai. Jan Kit Ching JK; Cheng. Christopher H K CH; Ko. Wing Hung WH; Leung. Po Sing PS
The researchers found that a type of pancreatic cell (AR42J) makes its own ghrelin and has ghrelin receptors. When ghrelin or a related peptide (GHRP‑6) is added, the cells show a two‑step rise in internal calcium, which can be blocked by specific inhibitors. This suggests the ghrelin system plays a role in how the exocrine pancreas works.
In goldfish, tiny amounts of the hormone ghrelin can make the pituitary gland release both growth hormone (GH) and the reproductive hormone luteinizing hormone (LH). The effect on GH can be stopped by another hormone called somatostatin, while a drug that blocks the ghrelin receptor (GHRP‑6) blocks the LH boost but not the GH boost. Giving ghrelin to fish raised their blood levels of LH and GH for a short time.
Yeung. Chung-Man CM; Chan. Chi-Bun CB; Cheng. Christopher H K CH
Researchers mapped the DNA region that controls the growth hormone secretagogue receptor (GHSR) gene in a fish called black seabream and found that activating the receptor with a GHSR agonist boosts its own gene activity, which is the opposite of what happens in humans.
Li. James J JJ; Wang. Haixia H; Qu. Fucheng F; Musial. Christa C; Tino. Joseph A JA; Robl. Jeffrey A...
Scientists made a new class of chemicals that can boost growth hormone in rats, with one version (carbamate 12a‑E2) raising GH levels about ten times. However, these compounds are experimental, not available to the public, and the study used an anesthetized rat model, so it doesn't give direct guidance for human use or for the peptide GHRP‑6.
Machado. M C MC; Sá. S V SV; Goldbaum. T S TS; Catania. M M; Campos. V C VC; Corrêa-Gianne...
In a 26‑year‑old man with Cushing's syndrome caused by a lung carcinoid tumor, giving the peptide GHRP‑6 caused a big jump in ACTH hormone levels. The tumor tissue showed high levels of the receptor that GHRP‑6 binds to (GHSR‑1a). Removing the tumor cured his symptoms, linking the hormone response to the receptor’s presence.
Lei. T T; Liu. Q Q; Li. L L; Zhang. L L; Shu. K K; Xue. D D
The study looked at how the peptide GHRP‑6 affects a signaling molecule (cAMP) in pituitary tumor cells. It found that GHRP‑6 raised cAMP levels only in tumors that carried a specific oncogene (gsp) and could boost the effect of another hormone (GHRH). This suggests the peptide can interact with certain cellular pathways, but the work was done in tumor tissue, not in healthy people.
Choi. S J SJ; Lee. H Y HY; Kim. S B SB; Kim. J H JH; Lee. S S SS; Yoo. S D SD; Lee. K C KC; Lee. H S...
Researchers created a lab test that can accurately measure the amount of the peptide GHRP‑6 in blood using a special chromatography setup and an electrochemical sensor. The method works well for low concentrations (5‑100 ng/ml) and uses a simple sample cleanup step.
Danila. George Madalin GM; Puiu. Mihaela M; Zamfir. Lucian-Gabriel LG; Bala. Camelia C
Scientists created a lab test that can spot chemicals that block the growth‑hormone‑releasing receptor (GHS‑R1a) in urine. They found that, oddly, these blockers actually make the natural hormone ghrelin stick to the receptor better when only tiny amounts are present. The test can measure how tightly both the hormone and the blockers bind to the receptor and works with several detection methods.
Baser. Tayfun T; Ozdemir. Ercan E; Filiz. Ahmet Kemal AK; Taskiran. Ahmet Sevki AS; Gursoy. Sinan S
In rats, giving the ghrelin‑like peptide hexarelin together with morphine made the pain‑killer work better and slowed down the usual loss of effect that happens with repeated doses. The ghrelin blocker [d‑Lys3]‑GHRP‑6 didn’t change morphine tolerance.
This review paper explains how growth hormone (GH) release is controlled by many signals from the brain and the body, and points out why that matters for health conditions. It doesn’t give new experiments or dosing tips for GHRP‑6, just a broad overview of the biology.
Studies of nesfatin-1 in glucose metabolism have become a topic of interest recently, however, the specific receptor for nesfatin-1 has not yet been identified. Some studies hinted at a connection between nesfatin-1 and the ghrelin receptor, growth hormone secretagogue receptor. Therefore, we aimed to study the role of GHSR in the glycemic effects of nesfatin-1 as well as its downstream pathways. We employed C57/BL6 mice (wild type and GHSR knockout mice) eating a normal chow diet and a high fat diet in this study, and the experimental technique included western blot, real-time PCR, immunofluorescence and ELISA. We found that in mice fed a normal chow diet (NCD), nesfatin-1 improved glucose tolerance, up-regulated AKT kinase (AKT) mRNA levels and phosphorylation and GLUT4 membrane translocation in skeletal muscle. These effects were blocked by co-injection of GHSR antagonist [D-Lys3]-GHRP-6 and were attenuated in GHSR knockout mice. In mice fed high-fat diet (HFD), nesfatin-1 not only exerted the effects observed in NCD mice, but also suppressed appetite and raised AKT levels in liver tissues that also required GHSR. Peripheral nesfatin-1 suppressed c-fos expression of GHSR immunoreactive neurons induced by fasting in hypothalamic nuclei, indicating that nesfatin-1 inhibited the activation of central GHSR. We concluded that the effects of nesfatin-1 on food intake and glucose metabolism were GHSR-dependent, and that the glycemic effect was associated with AKT and GLUT4. This study should stimulate further exploration of the nesfatin-1 receptor.
The neuroprotective and proangiogenic potential of ghrelin in acute ischemic stroke has been demonstrated in experimental studies. However, the transferability of these results is limited as ghrelin was administered either before or very early after stroke onset and follow-up was limited to the first days after stroke. The aim of this study was therefore to close and extend this knowledge gap. To this end, we investigated the effect of ghrelin in two different translational animal models, one investigating acute and one investigating long-term structural and functional recovery after experimental stroke.
Middle cerebral artery occlusion (MCAO) or photothrombotic stroke was induced in 65 adult male Wistar rats. Eleven sham-operated animals served as controls. The rats were treated with either ghrelin, the ghrelin receptor antagonist [D-Lys]-GHRP-6 or a control substance. Up to four weeks after ischemia, behavioral tests such as the cylinder test, the tape removal test, and the rotarod test were performed to examine sensorimotor deficits, and the Morris water maze was performed to examine effects on the acquisition and consolidation of new memories. The structural outcome was determined by a differential analysis of neurogenesis in relation to survival and proliferation of newborn neurons in the post-ischemic brain, angiogenesis and determination of infarct size.
Ghrelin treatment improved motor and somatosensory functions and preserved the consolidation of new memories after photothrombotic stroke. As a structural correlate, long-term survival and sustained proliferation of neuronal cells after stroke was significantly increased in ghrelin-treated rats, while angiogenesis remained unaffected. In contrast to these neuroregenerative mechanisms, ghrelin did not induce immediate neuroprotective effects after MCAO.
Our results suggest that ghrelin has a significant pro-neuroregenerative effect by enhancing long-term survival and sustained proliferation of neurons in the dentate gyrus and peri-infarct area, thus promoting functional recovery. Overall, ghrelin represents a promising target in the subacute and chronic phase after ischemic stroke.